Condition
Adenocarcinoma, Bronchiolo-Alveolar
Total Trials
4
Recruiting
0
Active
0
Completed
1
Success Rate
50.0%-37% vs avg
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 100/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
50.0%
-36.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
50% success
Data Visualizations
Phase Distribution
3Total
P 2 (3)
Trial Status
Unknown2
Completed1
Terminated1
Trial Success Rate
50.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT00384826Phase 2CompletedPrimary
Therapeutic Strategy in Advanced Bronchioloalveolar Carcinoma
NCT02239432Unknown
Telomere Biology in Early Adenocarcinoma of the Lung
NCT00117351Phase 2Terminated
VELCADE in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC Features
NCT00339586Phase 2Unknown
First-Line EGFR-1 Tyrosine Kinase Inhibition in Patients With NSCLC With Mutant EGFR Gene
Showing all 4 trials